



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Regulatory Perspectives ICORD

Tokyo Feb 2012

Dr Agnes Saint-Raymond
Human Medicines Special Areas
European Medicines Agency

An agency of the European Union



Declaration of Interests

Full time employee of the European Medicines Agency

No conflicting interests (no grants, shares, patents, etc.)

Acknowledgements

Thanks to Jordi Llinares and the orphan team at EMA for the work and the slides

Thanks to Prof Kerstin Westermarck, Chair of the EMA Committee for Orphan Medicinal Products

What is the EMA?

An Agency of the European Union responsible for the scientific evaluation of **medicines** for human and animal use in the European Union (European Network):

- **Orphan Designation** for medicines for rare diseases*
- Scientific Advice*
- Paediatric activities*
- Marketing Authorisations and variations
- Inspections
- Innovation, methodology and statistics*
- Pharmacovigilance
- Article 58 with WHO
- SME office*

London, Canary Wharf



EMA

Outline

Overview orphan designation

Procedure and criteria

- Definition of a medical entity
- Significant benefit
- Outcomes
- Other activities
- Transparency

Outline

Overview orphan designation

Procedure and criteria

- Definition of a medical entity
- Significant benefit

Outcomes

Other activities

- Transparency

Why an orphan regulation?

Rare diseases → developing and marketing cost would not be recovered by the expected sales

Pharmaceutical industry does not develop medicines for rare diseases under normal market conditions

Persons suffering from rare conditions deserve treatment and same quality of medicines as other patients

Objectives of the European Regulation

- Provide incentives that stimulate research and development (push)
- Modify market conditions (pull)
- Set up a system of recognition of orphan medicines entitled to incentives
- Since 2000

Legal references in the EU

Regulation (EC) No 141/2000 of the European Parliament and of the Council on Orphan Medicinal Products of 16 December 1999

- Criteria for designation
- Committee (COMP)
- Procedure
- Incentives

Implementing **Commission Regulation (EC) No 847/2000** of 27 April 2000

Supplemented by:

Commission communication July 2003 (2003/C 178/02)

Commission communication on Art 8(1) and (3) (C(2008) 4077)

Main characteristics of orphan designation

For medicinal products for human use

Procedure free of charge, at EMA only:

- Can be requested at any stage of development

Sponsor can be either company or individual:

- Established in the European Union or EEA/EFTA (Ice, Liech, Nor)

Scientific opinion given by Orphan Committee (COMP)

European Commission makes Decision, which gives access to incentives

Incentives (1)

Fee reduction / exemptions

- Extended incentives for Small and Medium Sized Enterprises!
 - ➔ free protocol assistance
 - ➔ free marketing authorisation application
 - ➔ free post authorisation application and annual fee during first year from authorisation

Protocol Assistance

Incentives (2)

10-year **market exclusivity** (+ 2 for paediatric development)

- Protection against similar products
 - Same molecular structure
 - Same mechanism of action
 - Same granted indication
 - 3 derogations (allowing access to market when similar)
 1. Sponsor's consent
 2. Lack of supply
 3. Clinical superiority

Outline

Overview orphan designation

Procedure and criteria

- Definition of a medical entity
- Significant benefit

Outcomes

Other activities

- Transparency

Designation criteria

RARITY (prevalence) or RETURN ON INVESTMENT

Medical condition affecting no more than 5 in 10,000 persons in the European Union (around 250,000 patients affected)

or

Without incentives it is unlikely that the marketing of the product would generate sufficient return to justify the necessary investment

AND SERIOUSNESS

Life –threatening or chronically debilitating

AND NO SATISFACTORY METHODS AUTHORISED

If satisfactory method exists, the sponsor should establish that the product will be of **SIGNIFICANT BENEFIT**

Committee for Orphan Medicines (COMP)

- 1 Representative per Member State (27)
- 3 Patients' Representatives appointed by Eur. Commission
- 3 Members appointed by Eur. Commission on proposal from Agency
 - 1 Member for Norway, and 1 for Iceland
 - and 1 elected Chair (Prof. Kerstin Westermarck)
- As needed, experts and Observers



Outline

Overview orphan designation

Procedure and criteria

- Definition of a medical entity
- Significant benefit

Outcomes

New activities

- Transparency

'Medical condition' for Orphan designation

Defined in European Commission Guideline:

- Any deviation from the normal structure or function of the body, as manifested by a characteristic set of signs and symptoms (typically a recognised distinct disease or a syndrome)

Examples:

Duchenne Muscular Dystrophy

Gaucher disease

Mesothelioma

Additional considerations on 'condition'

- Distinct entity if justified by pathophysiology, histology, clinical presentation
- Development is plausible based on pathogenesis and pharmacodynamics

However:

- Different severities or stages of a common disease not acceptable:

Second-line treatment of ...

Patients refractory to ...



Outline

Overview orphan designation

Procedure and criteria

- Definition of a medical entity
- **Significant benefit**

Outcomes

New activities

- Transparency

Significant benefit – EU specifics

“A clinically relevant advantage or a major contribution to patient care”

- Based on assumptions at the time of orphan designation
- Shown over authorised products (=satisfactory methods), but comparative data not always required
- Significant benefit (and other orphan criteria) to be confirmed (data) prior to marketing authorisation
- COMP has worked on a Recommendation for the data on Significant Benefit and medical plausibility

'Assumption' of Significant Benefit

- Medicine has a new mechanism of action leading to
 - Better effect and potential better/greater efficacy (still to be demonstrated)
 - Opens possibilities for drug combinations, and broadens therapeutic alternatives
- More convenient administration route (= major contribution to patient care)
 - When documented problems exist with existing route
- Complementary (better) safety profile
 - Weak justification of significant benefit (which data to support?)



Outline

Overview orphan designation

Procedure and criteria


- Definition of a medical entity
- Significant benefit

Outcomes

Other activities

- Transparency


Use of EU subsidy (not fees from industry)




Use of \approx 6 million Euro per year



Outcome of orphan designation




Success rate ~70%







Orphan Designations and Prevalence



Orphan Designation by therapeutic area





Orphan Designation for paediatric conditions



- Medical conditions affecting adults only
- Medical conditions affecting both children and adults
- Medical conditions affecting children only

Orphan products authorised per therapeutic area (n=69)





Outline

Overview orphan designation

Procedure and criteria

- Definition of a medical entity
- Significant benefit


Outcomes

Other activities

- Transparency

Transparency of Orphan designations

- COMP monthly report (Opinions)
- EU Commission Register of orphan designated medicinal products (Decisions)
- Public summary of positive/negative opinion for orphan designation (at time of Decisions)
- Summary of review of orphan designation at time of Marketing Authorisation (since 2010) – Link with European Public Assessment Report



Human medicines

- European public assessment reports
- Patient safety
- Pending EC decisions
- Withdrawn applications
- Paediatrics

Rare disease designations

- Medicines for use outside the EU

Veterinary medicines

- Herbal medicines for human use

[Home](#) [Find medicine](#) [Human medicines](#) [Rare disease designations](#)

EU/3/10/752

[Email](#) [Print](#) [Help](#) [Share](#)

Orphan designation

Key facts

Review of designation

On 6 June 2010, orphan designation (EU/3/10/752) was granted by the European Commission to Shire Pharmaceuticals Ireland Limited, Ireland, for velaglucerase alfa for the treatment of Gaucher disease.

[Expand all items in this list](#)

- [What is Gaucher disease?](#)
- [What is the estimated number of patients affected by the condition?](#)
- [What treatments are available?](#)
- [How is this medicine expected to work?](#)
- [What is the stage of development of this medicine?](#)
- [Opinions on orphan medicinal product designations are based on the following three criteria:](#)

Name	Language	First published	Last updated
EU/3/10/752: Public summary of positive opinion for Velaglucerase alfa for the treatment of Gaucher disease	(English only)	23/06/2010	18/10/2010

Related information

[Vpriv: EPAR](#)

Sponsor's contact details:
Shire Pharmaceuticals Ireland Limited
5 Riverside Walk
Citywest Business Campus
Dublin 24
Ireland
Telephone: +353 1 4297700
Telefax: +353 1 4297701

International collaboration on rare diseases

Rare diseases share common needs / challenges (rationale for international approach)

Orphan medicines are developed at a global level

- Expertise is scarce and scattered
- Efficient use of resources
 - Low number of patients and geographically dispersed
 - Multi-centre/national trials (centres of reference)

Designation done in parallel or close in time

- Global market
- Pooling incentives

Collaboration in orphan designation

Administrative simplification

- Relatively simple and cost efficient
- Facts (US-EU):
 - common application form and common application format
 - Single submission of annual reports

Communication-collaboration during assessment

- Analysis of reasons for divergent opinions
- Sharing of information in real time: monthly teleconferences (regulatory experience)
- Sharing experts

Collaboration during medicine development

Scientific advice

- Parallel advice EU-US established
- Global development requires consistent/compatible advice (at least not contradictory!)
- Issues of trials and endpoints

Safety information exchange

Collaboration post authorisation

Safety issues / pharmacovigilance

- Sharing information on signals and alerts
- Adoption of similar measures (in the FUTURE?)

Establishment of common registers (in the FUTURE?)

- Coordination to avoid duplication / waste of resources
- Register structure should allow combination of data



The first steps already in place

Confidentiality arrangements

- EU-FDA
- EU-Japan
- EU-Canada
- EU- Australia

International liaison officers posted

Exchange of staff

Clusters for therapeutic areas, for orphan medicines, paediatrics, pharmacovigilance, etc.

- Monthly teleconferences
- Common projects

Establishment of a network of regulators for Orphan medicines

PROPOSAL:

Discussion and exchange forum

Stimulation of orphan policies in other countries

Need to agree on practical and realistic deliverables

Network that takes advantage of modern communication tools

Chair → Rota every 2 years?

Proposals for the network (1)

Promotion of orphan designation by

- Increasing awareness about designation procedures and incentives
- Increasing dialogue and understanding about designation criteria
- Administrative simplification within and between regulatory authorities
- Promoting existing incentives for orphan medicines
- Finding an advocate for medicine development for rare diseases in each regulatory authority


Proposals for the network (2)

Promotion of development of medicinal products for rare diseases

- Monitoring of current development of medicinal products for rare diseases
- Identification of unmet development needs
- Joint recommendations on the development of concrete measures to support – incentivise drug development

The Paediatric medicines Regulatory Network (PmRN) of WHO

Following ICDRA in 2008,
 a network was created:
 26 NRAs are participating.
 Monthly teleconferences
 Exchange of information
 Identify gaps and contribute to capacity building



Essential medicines for children

WHO > Programmes and projects > Essential medicines for children > Paediatric medicines Regulators' Network (PmRN)

Paediatric medicines Regulators' Network (PmRN)

There is a significant need for research and development of paediatric medicines. The lack of suitable paediatric medicines, paired with inconsistent regulatory frameworks, poses significant risks to a particularly vulnerable patient population.

As part of the WHO's Better Medicines for Children initiative a Paediatric medicines Regulator's Network (PmRN) has been set up with representatives from national medicines regulatory authorities (NMRAs) from all regions.

To read more about the objectives of the PmRN,
 :: [see...](#)

NMRAs are welcome to participate in the network. For further information, interested Member States are encouraged to contact: pnr_network@who.int

:: [List of Members as of 5 October 2010 \[pdf 24kb\]](#)

RELATED INFORMATION

:: [Meetings of the Paediatric medicines Regulator's Network \(PmRN\)](#)

:: [Prequalification Programme -- A United Nations Programme managed by WHO](#)

Clinical trials

:: [More information on paediatric medicines clinical trials](#)

Regulatory support

:: [Medicines regulatory support](#)

Safety


:: [Safety, efficacy and utilization](#)

MORE INFO

:: [Selection of essential medicines](#)

:: [Endorsements](#)

:: [More supporters](#)


 make medicines **Child Size**

Conclusions

ICORD is perfect opportunity to create a network of regulators

Raising awareness of orphan incentives across the world

Collaboration on difficult medicines development

Questions on Orphan Medicines and Designation
to:

Jordi.Llinares@ema.europa.eu

Head of Orphan medicines

EMA website: <http://www.ema.europa.eu>



© European Medicines Agency 2010.

Reproduction and/or distribution of this document is possible for non-commercial purposes provided that EMA is always acknowledged as the source in each copy.

Citations may be made, provided the source is always acknowledged. See:

<http://www.ema.europa.eu/htmls/technical/dmp/copyritel.htm>